Am­gen tar­gets physi­cians with biosim­i­lars ed­u­ca­tion cam­paign in ad­vance of ex­pect­ed 2023 break­out

With 2023 poised to be a big year for biosim­i­lars, Am­gen is mar­ket­ing to doc­tors to help them un­der­stand the bi­o­log­ic drugs — and get ready for pa­tient ques­tions.

Why will peo­ple be ask­ing more about biosim­i­lars this year? The main rea­son is Ab­b­Vie’s megablock­buster Hu­mi­ra will get its first biosim­i­lar com­pe­ti­tion in the US at the end of Jan­u­ary, fol­lowed by a raft of oth­er Hu­mi­ra biosim­i­lars launch­ing through­out the year. While that first Hu­mi­ra com­peti­tor is Am­gen’s own Am­je­vi­ta, its biosim­i­lar so­cial me­dia cam­paign is ed­u­ca­tion­al on­ly and does not in­clude any men­tion of its own prod­ucts.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.